期刊文献+

原核表达人MMP-2PEX片段对乳腺癌细胞BICR-H1的生长及转移的抑制

The Effects of Human PEX,a C-terminal Hemopexin-like Domain of MMP-2,on the Growth and Metastasis of Human Breast Cancer BICR-H1 Cells
原文传递
导出
摘要 目的:克隆表达人源基质金属蛋白酶-2(MMP-2)的C-端类血红素结合域片段PEX,在鸡胚脲囊膜模型上研究PEX对血管发生,乳腺癌BICR-H1的生长及转移抑制作用。方法:构建人源PEX的原核表达载体pET-28a(+)-PEX-His,转化大肠杆菌BL21DE3-pLys,异丙基β-D硫代半乳糖苷(IPTG)诱导PEX蛋白;包涵体蛋白经尿素变性后,通过Ni-NTA琼脂糖鏊合柱纯化、复性蛋白;观察其对人脐静脉血管内皮细胞增殖和鸡胚脲囊膜血管生长的影响;用带有绿色荧光蛋白(GFP)的腺病毒感染高转移人乳腺癌细胞BICR-H1,接种细胞到10日鸡胚脲囊膜上致瘤,通过静脉注射不同剂量PEX后,观察瘤重、体积和肺转移。结果:5~30μg经原核表达纯化的人PEX蛋白能有效抑制人脐静脉血管内皮细胞增殖能力,表现为时间和剂量依赖效应,并可抑制鸡胚脲囊膜血管发生。BICR-H1的生长及转移在10μg PEX作用时可得到有效抑制,30μg时则完全抑制,未见有肿瘤在接种部位的形成,更未观察到肺脏的转移灶。结论:原核表达纯化的人源PEX具有抑制血管生成、进而抑制乳腺癌BICR-H1细胞的生长和转移作用,是潜在的抗血管发生治疗肿瘤药物,有进一步研发价值。 Objective:This study was designed to express human MMP-2 C-terminal hemopexin-like domain(PEX) in E.coli,and then to test its biological effects on angiogenesis,as well as on the growth and metastasis of human breast cancer BICR-H1 cells.Method:PEX was cloned into prokaryotic expression vector pET28a(+) and was induced to express in BL21(DE3)-pLys by IPTG.PEX-His fusion protein,which existed in the inclusion bodies,was denatured by urea method,then was renatured and purified though Ni-NTA agarose beads.The purified PEX-His was further characterized for its biological effects on angiogenesis inhibition,as well as on the suppression of the growth and metastases of human breast cancer BICR-H1 cells by employing the CAM assay.Results: Human PEX expressed in E.coli was able to inhibit the growth of human umbilical vein endothelial cells in a time and dose dependent manner,and could effectively inhibit the CAM angiogenesis.Furthermore,the growth and metastases of BICR-H1 cells were suppressed significantly by injection of 10μg PEX through the vein of chicken embryos,and they were completely disappeared when 30μg PEX was administrated.Conclusion: Human PEX expressed in E.coli is an effective angiongenesis inhibitor.It can inhibit the growth and metastases of BICR-H1 cells,and it might be useful in the treatment of angiongenesis associated diseases such as cancer.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2011年第3期13-17,共5页 China Biotechnology
基金 国家"863"计划(2006AA02A402) 国家自然科学基金(30572160 30971494) 北京市自然科学基金(7002009 7021001) 教育部新世纪优秀人才专项基金(NCET-07-0031)资助项目
关键词 PEX 血管发生 BICR-H1 乳腺癌 PEX Angiogenesis BICR-H1 Breast cancer
  • 相关文献

参考文献13

  • 1Alfano R W, Leppla S H, Liu S H, et al. Inhibition of tumor angiogenesis by the matrix metalloproteinase- activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid Mol Cancer Ther, 2010,9 ( 1 ) : 190 -201.
  • 2Brooks P C, Silletti S, Schalscha T L, et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell, 1998, 92(3) : 391 400.
  • 3Yoshifumi I, Akiko T, Noriko I, et al. Homophilic complex formation of MT1 -MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J, 2001, 20 (17) : 4782-4793.
  • 4Seung-K K, Theresa G, Cargioli, et al. PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model. Clin Cancer Res, 2005,11(16) : 5965-5970.
  • 5宋琳,张志谦.MMP-9信号肽高效诱导PEX重组蛋白在COS7细胞中分泌表达[J].中国生物工程杂志,2007,27(5):1-5. 被引量:3
  • 6Song L, Zhang Z Q. China Biotechnology, 2007, 27 (5) : 1-5.
  • 7Watanabe J, Endo Y, Shimada N, et al. Antiangiogenic activity of TZT-1027 (Soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells. In Vivo, 2007, 21 (2) : 297 -304.
  • 8邵会媛,苗宗玉,覃凤娴,陈先春,谭诗,钟梁,张伶.NPM1突变基因表达抑制K562白血病细胞体外增殖和侵袭[J].中国生物工程杂志,2010,30(11):6-10. 被引量:2
  • 9Shao H Y, Miao Z Y, Qin F X, et al. China Biotechnology, 2010, 30(11) :6-10.
  • 10Bobek V, Plachy J, Pinterova D, et al. Development of a green fluorescent protein metastatic-cancer chick-embryo drug-screen model. Clin Exp Metastasis. 2004, 21 ( 4 ) :347 -352.

二级参考文献22

  • 1张志谦,李金萍,胡颖.生长激素信号肽可诱导重组蛋白外分泌表达[J].中国生物化学与分子生物学报,2005,21(2):282-286. 被引量:4
  • 2Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1 ; molecular basis and clinical implications. Leukemia, 2009, 23 ( 10 ) : 1731- 1743.
  • 3Meani N, Alcalay M. Role of nucleophosmin in acute myeloid leukemia. Expert Rev Anticancer Ther, 2009, 9 ( 9 ) : 1283- 1294.
  • 4Zhang Y, Zhang M, Yang L, et al. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leukemia Research, 2007, 31 ( 1 ) : 109-111.
  • 5Piccaluga P P, Sabattini E, Bacci F, et al. Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. Leukemia, 2009, 23 (7) : 1370- 1371.
  • 6Cheng K, Grisendi S, Clohessy J G, et al. The leukemiaassociated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene, 2007, 26(53):7391-7400.
  • 7den Besten W, Kuo M L, Williams R T, et al. Myeloid Leukemia-Associated Nucleophosmin Mutants Perturb p53- Dependent and Independent Activities of the Arf Tumor Suppressor Protein. Cell Cycle, 2005, 4( 11 ) : 1593-1598.
  • 8Bonetti P, Davoli T, Sironi C, et al. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7γ. J Cell Biol, 2008, 182(1) : 19-26.
  • 9Falini B, Nicoletti I, Martelli M F, et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin ( NPMc + AML) : biologic and clinical features. Blood, 2007, 109 ( 3 ) : 874-885.
  • 10Schneider F, Hoster E, Unterhalt M, et al. NPM1 but not FLT3- ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood, 2009, 113 (21) : 5250-5253.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部